Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia
Clinical trial NCT05369377 · UNKNOWN
Trial details
- NCT number
- NCT05369377
- Sponsor
- Peking University People's Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-01
- Primary completion
- 2025-06-01
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.